IN8bio, Inc. develops gamma-delta (γδ) T cell therapies and γδ T cell engagers for cancer and autoimmune diseases. Company news centers on clinical and preclinical pipeline updates, including DeltEx Drug-Resistant Immunotherapy γδ T cells in newly diagnosed glioblastoma, INB-100 allogeneic γδ T cells for high-risk leukemias after haploidentical stem cell transplantation, and γδ T cell engager work for oncology and autoimmune indications.
Recurring updates also cover financial results, clinical data presentations at medical meetings, R&D communications, financing activity, Nasdaq inducement grants, and leadership or board changes. The company operates as a clinical-stage biopharmaceutical issuer with common stock traded on Nasdaq under INAB.
IN8bio presented results from their fully enrolled Phase 1 trial of INB-200 at the Society for Neuro-Oncology Annual Meeting. 50% of patients receiving repeated doses (n=10) remained alive and in remission beyond expected median overall survival, while single-dose patients (n=3) did not achieve this outcome. The trial demonstrated that 92% of evaluable patients surpassed median standard-of-care progression-free survival (PFS) of 6.9 months. Notably, multi-dose cohorts showed improved peripheral T cell recovery, with one patient remaining progression-free at 40.5 months. Biopsy results confirmed gamma-delta T cell presence in the brain tumor microenvironment. The treatment showed no serious adverse events, with most common side effects being Grade 1-2 toxicities.
IN8bio (NASDAQ: INAB) reported Q3 2024 financial results and corporate updates. The company reported that 100% of Acute Myeloid Leukemia patients treated with INB-100 remain in complete remission. The INB-100 trial is expanding enrollment to approximately 25 patients. Financial highlights include R&D expenses of $3.3 million (down from $3.8 million YoY), G&A expenses of $2.7 million (down from $3.4 million YoY), and a net loss of $7.1 million ($0.15 per share). The company secured $11.6 million through a private placement in October 2024, extending cash runway through 2025.
IN8bio (Nasdaq: INAB) announced an upcoming plenary oral presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) in November 2024. The presentation will provide extended follow-up data from the Phase 1 trial of INB-200, their gamma-delta T cell therapy for newly diagnosed glioblastoma.
Previous data presented at ASCO in June 2024 showed that 92% of evaluable patients exceeded the median progression-free survival of 7 months typically observed with standard-of-care therapy. The presentation will be delivered by Dr. Mina Lobbous from Cleveland Clinic Lerner College of Medicine.
IN8bio (Nasdaq: INAB) has announced an upcoming poster presentation at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, December 7-10, 2024. The presentation will focus on INB-100, a pilot study of donor-derived gamma-delta T cell therapy following haploidentical hematopoietic stem-cell transplantation. Dr. Joseph McGuirk from The University of Kansas Cancer Center will present Abstract #4823 in the Cellular Immunotherapies session on December 9, 2024, from 6:00 PM to 8:00 PM PDT. The abstract will be available online through ASH's website, with poster reprints accessible on IN8bio's website after the presentation.
IN8bio, Inc. (Nasdaq: INAB) has announced a $12.4 million private placement to fund its current operating plan into 2026. The financing will support the ongoing expansion cohorts in the Phase 1 trial of INB-100 for patients with Acute Myeloid Leukemia (AML). The private placement includes the sale of 25,759,595 shares of common stock, pre-funded warrants for 5,646,853 shares, and warrants to purchase up to 31,406,448 shares.
The proceeds will enable IN8bio to increase enrollment to approximately 25 patients in the expansion cohort at the recommended Phase 2 dose, with completion expected in the first half of 2025. Long-term follow-up results are anticipated in late 2025 and 2026. The company also plans to add a parallel control cohort to assess leukemia patients and compare INB-100 treatment to standard haplotransplantation.
IN8bio (Nasdaq: INAB) has announced a strategic pipeline prioritization and workforce reduction to optimize resource allocation. The company will focus on its INB-100 program for Acute Myeloid Leukemia (AML), which has shown promising results with 100% progression-free survival as of August 30, 2024. IN8bio will suspend enrollment in its Phase 2 clinical trial of INB-400 for glioblastoma (GBM) while continuing to monitor patients in both INB-400 and INB-200 trials.
The company plans to reduce its workforce by 49% and implement cash compensation reductions for executives and board members. These measures are expected to result in clinical cost savings and help preserve cash resources. IN8bio aims to complete additional enrollment for the INB-100 trial in the first half of 2025, with long-term follow-up results anticipated in late 2025 and 2026.
IN8bio, a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. William Ho, CEO and co-founder of IN8bio, will be presenting in a fireside chat format on Monday, September 9, 2024, at 2:30 p.m. ET.
The presentation will be accessible via a live webcast, with a replay option available afterwards. Interested parties can find the webcast under the "Events and Presentations" section of the IN8bio website at https://investors.in8bio.com. This event provides an opportunity for investors and analysts to gain insights into IN8bio's innovative approach to cancer treatment using gamma-delta T cell therapies.
IN8bio (Nasdaq: INAB) has solidified its position as a clinical leader in gamma-delta T cell therapy for oncology. The company reported 100% of treated acute myeloid leukemia (AML) patients remain in complete remission. IN8bio received FDA guidance for a registrational trial of INB-100, with IND submission anticipated in Q1 2025. Early clinical data shows prolonged relapse-free survival in both AML and glioblastoma (GBM) programs, surpassing current standard-of-care. Both programs are advancing to Phase 2 clinical development. The company is the first to report improvements in relapse-free survival in both solid and hematological cancers using allogeneic or autologous gamma-delta T cells.
IN8bio (NASDAQ: INAB) reported Q2 2024 financial results and corporate highlights. Key points include:
1. Presented 100% 1-year complete remission in evaluable patients with hematologic malignancies for INB-100 at EHA 2024.
2. Demonstrated 92% of glioblastoma patients treated with INB-200 exceeded median seven-month progression-free survival at ASCO 2024.
3. Showcased robust manufacturing platform for DeltEx gamma-delta T cells at ASGCT 2024.
4. Q2 2024 financials: R&D expenses increased to $5.2 million, net loss was $8.6 million ($0.19 per share), and cash position as of June 30, 2024, was $10.2 million.
IN8bio continues to advance its gamma-delta T cell therapies for solid and hematologic cancers, showing promising results in clinical trials.
IN8bio, a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, announced that its CEO and Co-founder, William Ho, will be participating in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.
The event is scheduled for June 25, 2024, at 2:30 p.m. ET. The presentation will include a fireside chat, providing insights into IN8bio's advancements and future plans.
A live webcast and replay of the presentation will be accessible under the 'Events and Presentations' section on the IN8bio website.